Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) PT at $56.33

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have received an average recommendation of “Moderate Buy” from the eight brokerages that are currently covering the firm, Marketbeat reports. Four analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $56.33.

Several brokerages recently issued reports on AGIO. Royal Bank of Canada lifted their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Scotiabank lifted their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Finally, Raymond James reissued an “outperform” rating and issued a $51.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th.

Insider Activity

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the transaction, the insider now directly owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.93% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in AGIO. Venturi Wealth Management LLC bought a new stake in Agios Pharmaceuticals in the fourth quarter valued at about $33,000. Wingate Wealth Advisors Inc. bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at about $53,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Agios Pharmaceuticals by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 363 shares during the period. CWM LLC boosted its stake in Agios Pharmaceuticals by 554.7% during the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after acquiring an additional 1,836 shares during the last quarter. Finally, Quest Partners LLC grew its holdings in Agios Pharmaceuticals by 139.6% during the third quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 1,283 shares during the period.

Agios Pharmaceuticals Price Performance

Shares of AGIO stock opened at $34.38 on Thursday. The stock’s fifty day simple moving average is $38.84 and its 200 day simple moving average is $44.10. Agios Pharmaceuticals has a one year low of $23.41 and a one year high of $62.58. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of 3.03 and a beta of 0.88.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.